Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has unveiled promising outcomes from the KARDIA-2 Phase 2 investigation, evaluating the effectiveness and safety of zilebesiran when combined with one of three standard antihypertensive medications: a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine), or…
BioNTech SE (Nasdaq: BNTX) has released promising findings from a Phase 1 trial involving the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) for patients with resected pancreatic ductal adenocarcinoma (PDAC). The study, conducted over…
Merck, known as MSD outside of the United States and Canada, has announced the commencement of a Phase 3 clinical trial to evaluate MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the initial treatment of…
The recent occurrences of avian influenza outbreaks, observed last year, underscore the sobering reality of zoonotic influenza. These events emphasize that individuals of all ages are susceptible, regardless of comorbidities, and that various exposures can lead to avian influenza infection.…
Last year witnessed several outbreaks that underscore the reality of zoonotic influenza, revealing vulnerabilities across all age groups and highlighting the risks for individuals both with and without comorbidities. These outbreaks also emphasized the various exposures that can lead to…
Novartis Unveils Positive CHMP Endorsement for Fabhalta® in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis has disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion, recommending the authorization…
WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its recognition for exemplary corporate transparency and commitment to water security by the esteemed environmental non-profit CDP, securing its position on the prestigious annual…
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion, recommending the granting of marketing authorization for BIMZELX® (bimekizumab) within…
Pfizer Inc. (NYSE: PFE) has disclosed promising findings from a Phase 3 clinical trial investigating the efficacy of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in conjunction with lenalidomide and rituximab for treating patients afflicted with relapsed/refractory diffuse large B-cell lymphoma…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the successful approval of all proposed resolutions by its shareholders at the Annual General Meeting. The meeting saw 77.02% of the total 106,691,000 shares represented by 635 shareholders in attendance. Notably, approvals…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has announced the successful outcome of the Phase 3 KEYNOTE-A18 trial, also recognized as ENGOT-cx11 This trial assessed KEYTRUDA, Merck’s anti-PD-1 therapy, combined with chemoradiotherapy (CRT) for…
In Lisbon, Portugal, the World Health Organization (WHO) recently hosted an expert panel to reassess the Toxic Equivalency Factors (TEFs) for chlorinated dioxin-like compounds, initially established in 2005. Background: Since the 1990s, WHO has consistently organized expert consultations aimed at…